EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor–Positive Breast Cancer
- 16 July 2018
- journal article
- research article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 19 (1), 17-26.e8
- https://doi.org/10.1016/j.clbc.2018.07.011
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast CancerJNCI Journal of the National Cancer Institute, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trialBritish Journal of Cancer, 2011
- Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancerBMC Cancer, 2009
- The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast CancerCancer Research, 2008
- An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerThe New England Journal of Medicine, 2004
- Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimationStatistics in Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002